Illumina spins off GRAIL, a cancer detection tech company, as an independent Nasdaq-listed entity.
Illumina completed the spin-off and divestiture of GRAIL, now a public, independent company trading on Nasdaq under the ticker symbol "GRAL". Illumina retains a 14.5% minority share in GRAIL, with its focus on cancer detection technology. GRAIL had previously aimed for a Nasdaq IPO in 2020, raising almost $2 billion for its Galleri multi-cancer detection test, though its market cap now stands at $580 million.
June 24, 2024
6 Articles